Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20356524 | 0.87 | MDM2 (0.39) | MBOAT4MRGPRX4MDM2 | |
| SCHEMBL20356569 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDHTTHSD17B10 | |
| SCHEMBL21526039 | 0.85 | HTT (0.46) | ALDH1A1LMNAHPGDHTTHSD17B10 | |
| SCHEMBL20356565 | 0.84 | NPSR1 (0.40) | MRGPRX4ALDH1A1LMNAHPGDHTT | |
| SCHEMBL21525996 | 0.81 | SMN1; SMN2 (0.48) | ALDH1A1LMNAHPGDHTTHSD17B10 | |
| SCHEMBL21526102 | 0.80 | SMN1; SMN2 (0.47) | ALDH1A1LMNAHPGDHTTHSD17B10 | |
| Tert-Butylamine SCHEMBL21526135 | 0.78 | SMN1; SMN2 (0.44) | ALDH1A1LMNA | |
| SCHEMBL20356658 | 0.77 | NPSR1 (0.37) | MRGPRX4MDM2ALDH1A1LMNAHPGD | |
| SCHEMBL20356564 | 0.77 | CCR4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL21526047 | 0.76 | NPSR1 (0.37) | MRGPRX4MDM2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018124000-A1 | PYRIMIDINE DERIVATIVE | 第一三共株式会社 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034659-B2 | Pyrimidine derivative | GPR39, CFTR, TMEM109 | MBOAT4 4121/4885MRGPRX4 308/4885RORC 2097/4885 |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | GPR39, CFTR, TMEM109 | MBOAT4 4121/4885MRGPRX4 308/4885RORC 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.